Klein Hersh Recruits CEO for Corrixr Therapeutics
June 11, 2026 – Klein Hersh, a search firm focused on the life sciences and healthcare industries, has placed Hilary M. Malone as the new CEO of Corrixr Therapeutics in Newark, DE. She succeeds Eric B. Kmiec, founder of Corrixr, who will continue to serve in his capacity as chief scientific officer and will remain actively engaged in the company’s scientific direction.
“Hilary’s appointment marks a critical step in our shared mission to bring a fundamentally new approach to patients with squamous cell cancers,” said Janice E. Nevin, chair of the Corrixr board and president and CEO of ChristianaCare. “Corrixr has built a compelling body of scientific evidence, and we believe Hilary has precisely the experience and vision to translate that science into the clinic and beyond. ChristianaCare is proud to be Corrixr’s founding institutional investor and partner, and we look forward to supporting the next chapter of this work.”
Dr. Malone brings more than 25 years of executive leadership experience across both multinational pharmaceutical companies and venture-backed biotech startups, combining deep expertise in science, regulatory strategy, clinical development, and patient/market access across the full drug development lifecycle. She is joining Corrixr at a pivotal moment as the company advances its lead program, CXR101, toward IND filing and first-in-human proof-of-mechanism trials.
“I’m excited to join Corrixr at this important juncture, to lead the company and drive this ground-breaking science forward into clinical development,” said Dr. Malone. “Corrixr has built a rigorous preclinical foundation, a differentiated mechanism, and a clear path to the clinic. We now have a tremendous opportunity to bring a potentially transformative treatment to thousands of patients suffering from head & neck, lung and esophageal squamous cell cancers – indications where patients and physicians have been waiting a long time for something truly effective. I’m looking forward to working with this great team to advance CXR101 into first-in-human trials and building Corrixr into the defining company in eliminating squamous cell cancers.”
Dr. Malone is a seasoned biotech CEO and drug development executive with a 25+ year career spanning global regulatory affairs, clinical and CMC development, and early-stage company leadership across small molecules, biologics, vaccines, and cell and gene therapies. Most recently, she served as CEO of Stylus Medicine and, prior to that, as CEO of Certego Therapeutics. Her earlier career includes senior executive roles in major pharmaceutical companies, including Sanofi, where she served as chief regulatory officer and head of global regulatory affairs; Reata Pharmaceuticals; Pfizer/Wyeth; AstraZeneca; and GSK. Dr. Malone also served as chief operating officer, Therapeutics, at Valo Health. She currently serves on the board of Hansa Biopharma and holds a PhD in Neuropharmacology.
Related: Klein Hersh Places President and CEO for Damora Therapeutics
Established in 1998, Klein Hersh is an executive search firm that partners with clients to deliver executive leaders for global pharmaceutical, biotech, and healthcare companies as well as operating businesses of PE and VC-backed investments. Noteworthy clients include Akero, Aktis Oncology, Apogee Therapeutics, ArchWell Health, Atlas Venture, Bain Capital Life Sciences, Biogen, Capital Rx, ConcertAI, CytoReason, Dispatch, Fairmount, Forbion, Foresite Capital, Frazier Healthcare Partners, Iambic, ITM, Koa Health, LifeMine, LongueVue Capital, Lyric, MacroHealth, McKesson, Moderna, Morningside, Odyssey Therapeutics, Oruka Therapeutics, Pacira Biosciences, Inc., Paragon Therapeutics, Posterity Health, Revolution Medicines, TPG, Transformation Capital, Treeline Biosciences, and Unlearn.
AMR Clinical Search
Klein Hersh also recently recruited Bernard Dyson as CFO of AMR Clinical (AMR), an award-winning clinical research site company. He joins AMR’s executive leadership team to lead the company’s financial strategy and support its continued growth across therapeutic areas and geographies. Mr. Dyson will serve as a key member of the executive leadership team, helping guide AMR Clinical through its next phase of expansion and innovation in clinical research.
“Bernard brings an exceptional combination of financial leadership, operational expertise, and strategic vision,” said Kari L. Delahunty, CEO of AMR Clinical. “As the clinical research industry continues to evolve, AMR is uniquely positioned to connect sponsors, sites, and patients through community-based engagement, therapeutic expertise and patient recruitment solutions. Bernard’s experience scaling organizations and driving sustainable growth will be instrumental as we continue to expand our impact and deliver value to our partners.”
Mr. Dyson brings decades of life sciences and clinical research industry experience, supporting growth initiatives and aligning financial strategy with operational execution. “AMR has built a differentiated clinical research platform with strong momentum and a clear vision for the future. Having spent my career in clinical research and strategic finance, I look forward to partnering with the team to support AMR’s next phase of growth,” he said.
Related: Klein Hersh Assists Artios Pharma with CEO Search
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
